China Shines For Lilly Despite Cloudy Volume Purchasing, COVID-19 Forecast
Tyvyt A Star Performer
Lilly for the first time breaks out its China business after reporting whopping 93% volume growth in Q1 and a 30% rise in constant currency terms in the first major coronavirus-stricken country.
You may also be interested in...
As the first major country apparently emerging from the coronavirus outbreak, China offers a ray of hope for healthcare companies struggling with a large drop in prescriptions and vaccine use as the outbreak continues to wreak havoc in the US, Europe, Japan and emerging markets.
The pharma saw a $250m revenue increase due to inventory stockpiling and early prescription renewals, but its therapies outside cancer and diabetes may suffer in the coming quarters due to COVID-19.
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.